CA
NZ
UK
AU
IND
US
…
NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. Its product pipeline comprises givastomig, a potential CLDN18.2 bispecific antibody, which is in phase 2 clinical trial combination with nivolumab and chemotherapy for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies; Phase 1b clinical trial in combination with nivolumab and chemotherapy in first-line gastric cancer. The company also develops VIS-101, VEGF-A × ANG-2 bispecific biologics in Phase 2 clinical trial to treat wet age-related macular degeneration and other retinal diseases, including diabetic macular edema; ragistomag, which is in Phase 1clinical trial for multiple solid tumors. It has a licensing agreement with AskGene to develop and commercialize VIS-101; collaborations with Bristol Myers Squibb for the development of givastomig; and license and collaboration agreement with AbbVie Ireland Unlimited Company for the development and commercialization of lemzoparlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -12.63M | -362.73M | -1465.69M | -973.17M | -2332.04M |
| Minority interest | 42.07M | 0.00M | 0.00M | - | - |
| Net income | -6.61M | -162.26M | -1465.69M | -967.52M | -2331.54M |
| Selling general administrative | 4.48M | 216.46M | 63.91M | 199.88M | 899.94M |
| Gross profit | -0.86M | - | 4.49M | -10.70M | 41.59M |
| Reconciled depreciation | 0.86M | 0.98M | 1.06M | 1.42M | 5.36M |
| Ebit | -13.48M | -375.36M | -347.62M | -366.08M | -2071.31M |
| Ebitda | -13.35M | -373.45M | -344.25M | -356.38M | -2057.53M |
| Depreciation and amortization | 0.12M | 1.91M | 3.37M | 9.70M | 13.78M |
| Operating income | -13.48M | -375.36M | -511.16M | -366.08M | -2071.31M |
| Other operating expenses | 13.48M | 375.36M | 515.65M | 355.38M | 2159.33M |
| Interest expense | - | - | 0.10M | 0.00M | 0.00M |
| Tax provision | 0.00M | 0.00M | 0.00M | 0.10M | -0.49M |
| Interest income | 7.61M | 7.49M | 9.29M | 4.95M | 3.35M |
| Net interest income | 7.61M | 7.49M | 9.29M | 4.95M | 3.35M |
| Income tax expense | - | - | -1258.93M | -5.65M | -0.49M |
| Total revenue | 0.00M | 0.00M | 4.49M | -10.70M | 88.03M |
| Total operating expenses | 13.48M | 375.36M | 515.65M | 355.38M | 2112.90M |
| Cost of revenue | 0.86M | - | 0.00M | 27.24M | 46.43M |
| Total other income expense net | 0.85M | 12.63M | -954.53M | -607.09M | -260.73M |
| Net income from continuing ops | -88.34M | -49.70M | -82.22M | -141.20M | -365.78M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 37.24M | 1552.31M | 368.92M | 4073.66M | 878.74M |
| Intangible assets | - | - | 16.66M | 118.89M | 18.77M |
| Other current assets | 0.70M | 24.05M | 16.35M | 252.51M | 13.99M |
| Total liab | 4.23M | 84.08M | 126.34M | 1065.34M | 163.42M |
| Total stockholder equity | 33.02M | 1468.23M | 242.58M | 3008.33M | 715.33M |
| Other current liab | 3.72M | 55.75M | 57.52M | 651.33M | 92.71M |
| Common stock | 0.00M | 0.14M | 0.02M | 0.13M | 0.02M |
| Capital stock | 0.03M | 0.02M | 0.02M | 0.02M | 0.02M |
| Retained earnings | -190.47M | -9386.54M | -1263.81M | -6766.65M | -683.21M |
| Good will | - | - | 0.00M | 162.57M | 25.51M |
| Other assets | -21751999782.48M | - | - | - | - |
| Cash | 30.11M | 498.24M | 291.51M | 3214.01M | 552.80M |
| Total current liabilities | 3.84M | 61.70M | 58.14M | 659.74M | 97.90M |
| Current deferred revenue | - | 0.77M | 1.58M | 2.19M | 0.37M |
| Net debt | -29.67M | -469.90M | -287.62M | -3175.72M | -535.16M |
| Short term debt | 0.13M | 5.96M | 0.63M | 6.22M | 4.81M |
| Short long term debt | - | - | 4.23M | 2.75M | - |
| Short long term debt total | 0.44M | 28.33M | 3.89M | 38.29M | 17.64M |
| Other stockholder equity | 217.54M | 10610.97M | 1466.60M | 9558.13M | 1427.77M |
| Total current assets | 31.10M | 1289.65M | 329.91M | 3626.48M | 750.18M |
| Long term investments | 37.24M | 30.82M | 0.00M | 4.47M | 55.24M |
| Short term investments | 0.03M | 767.36M | 20.22M | 235.43M | 118.16M |
| Net receivables | 0.26M | 8.55M | 1.83M | 4.81M | 60.95M |
| Long term debt | - | - | 8.31M | - | - |
| Inventory | - | - | 28.95M | -80.28M | 4.27M |
| Accumulated other comprehensive income | 5.94M | 243.66M | 39.77M | 216.72M | -29.26M |
| Non currrent assets other | 0.40M | 9.96M | 33.46M | 10.91M | 4.18M |
| Non current assets total | 6.15M | 262.66M | 39.01M | 447.19M | 128.56M |
| Capital lease obligations | 3.07M | 3.88M | 3.89M | 8.12M | 17.64M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 104.92M | -136.01M | -15.16M | -5.18M | -114.09M |
| Total cashflows from investing activities | 104.97M | -992.42M | -107.63M | 458.38M | -727.21M |
| Net borrowings | - | - | 9.86M | 2.75M | 0.00M |
| Total cash from financing activities | 57.73M | -2.44M | -8.25M | 42.36M | 593.92M |
| Net income | -88.34M | -362.72M | -208.18M | -2507.32M | -2331.54M |
| Change in cash | 142.37M | -1706.19M | -151.58M | -212.86M | -1235.15M |
| Begin period cash flow | 68.26M | 2204.27M | 462.92M | 3523.63M | 4758.78M |
| End period cash flow | 210.63M | 498.07M | 311.34M | 3310.77M | 3523.63M |
| Total cash from operating activities | -20.60M | -384.29M | -72.85M | -1102.81M | -973.09M |
| Issuance of capital stock | 61.71M | 0.00M | 0.00M | 0.00M | 0.00M |
| Depreciation | 0.86M | 7.14M | 1.06M | 63.82M | 34.14M |
| Other cashflows from investing activities | 0.05M | 0.45M | -107.47M | 0.03M | - |
| Change to inventory | - | - | 0.00M | 27.24M | -27.24M |
| Change to account receivables | - | 0.00M | 0.00M | 33.08M | 97.42M |
| Sale purchase of stock | 0.00M | -2.45M | -8.66M | -3.08M | 0.00M |
| Other cashflows from financing activities | -4.19M | - | 0.41M | 42.69M | 593.92M |
| Capital expenditures | 0.01M | 0.35M | 0.16M | 45.83M | 29.93M |
| Change in working capital | 17.07M | -20.52M | -37.20M | 552.06M | 394.52M |
| Stock based compensation | 5.97M | -14.23M | 10.26M | 357.15M | 608.61M |
| Other non cash items | 43.84M | 5.90M | 161.20M | 431.48M | 321.18M |
| Free cash flow | -20.60M | -384.77M | -73.02M | -1148.63M | -1003.02M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| NBP NovaBridge Biosciences |
-0.02 2.23% |
0.84 | - | 2.68 | 25.39 | 0.93 | 0.14 |
| NVO Novo Nordisk A/S |
-0.54 1.32% |
40.55 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-2.37 0.43% |
544.66 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
-2.77 0.29% |
956.64 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. Its product pipeline comprises givastomig, a potential CLDN18.2 bispecific antibody, which is in phase 2 clinical trial combination with nivolumab and chemotherapy for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies; Phase 1b clinical trial in combination with nivolumab and chemotherapy in first-line gastric cancer. The company also develops VIS-101, VEGF-A × ANG-2 bispecific biologics in Phase 2 clinical trial to treat wet age-related macular degeneration and other retinal diseases, including diabetic macular edema; ragistomag, which is in Phase 1clinical trial for multiple solid tumors. It has a licensing agreement with AskGene to develop and commercialize VIS-101; collaborations with Bristol Myers Squibb for the development of givastomig; and license and collaboration agreement with AbbVie Ireland Unlimited Company for the development and commercialization of lemzoparlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.
| Name | Title | Year Born |
|---|---|---|
| Mr. Wei Fu | Executive Chairman | 1982 |
| Mr. Ming Lei | Chief Financial Officer | 1997 |
| Mr. Sean Wuxiong Cao M.B.A., Ph.D. | Chief Business Development Officer & Director | 1967 |
| Dr. Srishti Gupta M.D. | CEO & Director | 1976 |
| Mr. Mark Hagler | President & Chief Commercial Officer | NA |
| Mr. Tyler Ehler | Senior Director of Investor Relations | NA |
| Ms. Liwei Lin | General Counsel & Board Secretary | 1988 |
| Dr. Cong Xu M.D., Ph.D. | Senior VP and Head of R&D Center of Excellence | 1985 |
| Dr. Phillip Dennis M.D., Ph.D. | Chief Medical Officer | 1963 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.40%
Communication Services
-0.45%
Consumer Cyclical
-0.55%
Consumer Defensive
-0.01%
Energy
-0.01%
Financial Services
-0.40%
Financials
-0.15%
Healthcare
-1.15%
Industrials
-0.46%
Real Estate
-0.29%
Technology
-1.22%
Utilities
-0.10%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
+0.55%
Please wait processing your request...